相似文献
1
Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy.
Cancer Treat Rep. 1981 Jan-Feb;65(1-2):172-3.
2
Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
Cancer Treat Rep. 1981 Jan-Feb;65(1-2):137-41.
3
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Cancer Treat Rep. 1982 May;66(5):1233-4.
4
5
Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin.
Cancer Treat Rep. 1979 Aug;63(8):1375-7.
6
Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma.
Gynecol Oncol. 1982 Oct;14(2):262-70. doi: 10.1016/0090-8258(82)90098-1.
7
Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
Cancer Treat Rep. 1981 Jan-Feb;65(1-2):149-51.
8
The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
Semin Oncol. 1987 Dec;14(4 Suppl 4):12-9.
9
Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma.
Cancer Treat Rep. 1981 Jul-Aug;65(7-8):731-2.
10
Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
Obstet Gynecol. 1981 Aug;58(2):199-205.
Zotero 插件